Zepbound effective in obstructive sleep apnea trials STAT STAT
News Source : STAT
News Summary
- Eli Lilly reported positive results for its obesity drug Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market
- The results pave the way for the drug to potentially become the first approved treatment for OSA
- OSA is a common disorder characterized by breathing interruptions during sleep
Eli Lilly reported positive results for its obesity drug Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.The results also pave the way [+680 chars]